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Short ReportImmunodiagnostic Tests’ Predictive Values for
Progression to Tuberculosis in Transplant
Recipients
A Prospective Cohort Study
Laura Muñoz, MD,1,6 Aina Gomila, MD,1 Susana Casas, PhD,2 José Castellote, PhD,3 Montserrat Arnan, PhD,4
Antoni Rafecas, PhD,5 and Miguel Santin, PhD1,6
Background. Little is known about the predictive value for progression to tuberculosis (TB) of interferon-γ release assays and
how they compare with the tuberculin skin test (TST) in assessing the risk of TB infection in transplant recipients.Methods.We
screened 50 liver transplant (LT) and 26 hematopoietic stem cell transplant (HSCT) recipients with both QuantiFERON-TB
Gold In-tube (QFT-GT) and TSTand prospectively followed them for amedian of 47months without preventive chemoprophylaxis.
Results. In the LT cohort, 1 in 22 (4.5%) QFT-GT–positive patients developed posttransplant TB, compared with none of the
QFT-GT–negative patients. In the HSCT cohort, none of the 7 QFT-GT–positive patients developed TB, whereas 1 case (5.3%)
progressed to active TB among the 19QFT-GT-negative patients. Comparable results were obtainedwith the TST: in the LT group,
1 of 23 TST-positive and none of the 27 TST-negative patients developed TB; and in the HSCT group, none of the 8 TST-positive
and one of the 18 TST-negative patients progressed to active TB.Conclusions. In this cohort of transplant recipients, the pos-
itive predictive value of QFT-GT for progression to active TB was low and comparable to that of TST. Although the risk of devel-
oping TB in patients with negative results at baseline is very low, some cases may still occur.
(Transplantation Direct 2015;1:e12; doi: 10.1097/TXD.0000000000000520. Published online 1 April 2015)Transplant recipients are at increased risk for tuberculosis(TB) compared to the general population,1 although its
risk varies with the type of transplant and the endemic TB
burden.2-4 In low-prevalence regions, transplant-associated
TBmostly arises from the reactivation of a latent TB infection
(LTBI), which can be effectively prevented with proper treat-
ment.5 Therefore, guidelines strongly recommend screening
and treatment for LTBI for transplant candidates.1,6,7
The tuberculin skin test (TST) has been the reference
method for targeting TB chemoprophylaxis. However, itsReceived 29 November 2014. Revision requested 22 February 2015.
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ability to identify patients at higher risk of reactivation com-
promise its reliability in transplant candidates. These limita-
tions, together with the prevailing lack of awareness of the
risk of active TB and a fear of isoniazid toxicity,8 make phy-
sicians not offer universal LTBI treatment in this population.
The T cell–based interferon-γ release assays (IGRAs) have
been increasingly used for detecting LTBI in many clinical
scenarios. Although published data suggest that IGRAs
might perform better than TST in immunocompromised pa-
tients, such as transplant candidates,9 little is known about
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2 Transplantation DIRECT ■ 2015 www.transplantationdirect.comThis study aimed to assess the usefulness of the Quanti -
FERON-TB Gold In-tube (QFT-GT) for predicting the devel-
opment of active TB in comparison to the TST in patients
undergoing liver transplant (LT) and hematopoietic stem cell
transplant (HSCT) in a low-TB burden setting (17.3 per
100,000 population).15MATERIALS AND METHODS
We performed a prospective cohort study to evaluate the
performance of TST and QFT-GT for detecting LTBI in con-
secutive candidates to LT and HSCT between July 2008 and
July 2010 at Duran i Reynals and Bellvitge University Hospi-
tals in Barcelona (Spain). All patients provided written in-
formed consent before enrolment, and the ethics committee
approved the study.
Transplant candidates were referred to the TB unit for clin-
ical assessment and were asked to enrol after active TB had
been excluded. In accordance with current guidelines, we
followed a symptom-driven diagnostic workup for ruling
out active TB in our cohort. All patients were screened for re-
spiratory and had a chest x-ray performed. Because all our
patients were asymptomatic and there were no concerning
radiographic findings, no microbiologic testing was neces-
sary to evaluate for active TB infection.
Experienced staff took a blood sample for QFT-GT test-
ing, and TST was administered immediately after. For the
TST, any induration 5 mm or greater was considered posi-
tive.7 If the TST result was negative, another TST was ad-
ministered within a week to assess any booster effect. After
testing, patients were referred back to their treating phy-
sicians, who decided whether to treat them or not. In LTTABLE 1.
Baseline Characteristics of Liver and Hematopoietic Stem Cell T
Baseline Characteristics Liver Transplant, n = 5
Age: median (IQR), y 57.5 (51-64)
Male sex 38 (76)
Spanish born 45 (90)
Risk factors for TB 5 (10.0)
Birth/residence in a high-prevalence country 2 (4.0)
Exposure to active TB 2 (4.0)
Occupational exposure 1 (2.0)
Immunosuppressive treatment in the previous 6 months 3 (0.06)
BCG scar 15 (30.0)
Primary reason for transplant
Alcoholic or hepatitis virus cirrhosis 24 (48.0)
Hepatocellular carcinoma 20 (40.0)












BCG indicates Bacillus Calmette-Guerin.
Copyright © 2015 The Authors. Transplantation Dcandidates, the risk of liver toxicity was considered to out-
weigh the potential benefit of chemoprophylaxis regardless
of the TSTor QFT-GT results. The lack of specific guidelines
and the priority of treating a hematologic malignance also
meant no LTBI treatment for patients in the HSCT cohort.
By December 31, 2013, we checked on the statuses of pa-
tients by reviewing their medical charts and contacting their
physicians. We focused on transplant procedure and the de-
velopment of active TB and death. A definitive TB diagnosis
was defined as the isolation of Mycobacterium tuberculosis
complex in clinical samples, or a positivemolecular test result
and response to specific treatment. The incidence of active TB
was calculated both as a cumulative incidence and as a den-
sity incidence (events per person-year) with 95% confidence
intervals (95%CI). The positive/negative predictive values
for TB progression for each test were defined as the propor-
tion of patients with positive/negative results who did/did
not develop TB within the follow-up period, respectively.RESULTS
The initial cohort included 90 patients with end-stage liver
disease and 27 patients with hematologic malignancies that
were considered for LT and HSCT, respectively. However,
of the patients with end-stage liver disease scheduled for
LT, 24 died before transplantation, 16 improved without
LT, and 50 (55.6%) eventually received LT by the follow-up
date. All 27 patients with hematologic malignancies received
HSCT but we excluded 1 candidate because he was screened
for LTBI after transplantation.
The baseline characteristics of both cohorts are summa-
rized in Table 1. The prevalence of LTBI according to theransplant Recipients
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© 2015 Wolters Kluwer Muñoz et al 3QFT-GTwas 44% and 26.9% in the LT and HSCT cohorts,
respectively; 2 patients in the LT (2.6%) had indeterminate
results due to low production upon stimulation with phyto-
hemagglutinin. Regarding TST, 23 patients (46%) in the liver
cohort and 8 (30.8%) in the HSCT cohort presented with
positive reactions. Correlation of LTBI tests' results and tra-
ditional TB risk factors are shown in Table 2. Median time
from LTBI screening and transplantation was 15 days (inter-
quartile range [IQR], 8-23).
The LT cohort was followed up for a median of 47.5
months (IQR, 35.0-53.9) after transplantation, over which
period, 7 patients died, none was lost to follow-up, and
1 patient developed TB (incidence rate, 0.6 per 100 person-
years; 95%CI, 0.3-28.3). Hewas a 67-year-oldmanwith he-
patocellular carcinoma and positive QFT-GT and TST at
baseline, who presented with abdominal pain and anorexia
11 months after an orthotopic LT. A computed tomography
scan showed an ileocecal mass and a subsequent biopsy con-
firmed granulomatous inflammation. Culture from colonic
and liver biopsies yielded Mycobacterium tuberculosis com-
plex, and he made a complete recovery after a 9-month regi-
men of rifabutin, isoniazid, and levofloxacin.
The HSCT cohort was followed up for a median of
47.51 months (IQR, 27.0-57.5), and of the 26 participants,
7 patients died, 2 were lost to follow-up (after 113 and
370 days), and 1 patient developed TB (incidence rate, 1.1 per
100 person-years; 95% CI, 0.05-5.4). This patient was a
46-year-old woman who had tested negative for TST and
QFT-GT before receiving an allogeneic HSCT for acute leu-
kemia. Three months after transplantation, she developed
multiple organ dysfunction, which was attributed to pro-
gression of the leukemia. She died 15 days after being ad-
mitted to the intensive care unit. A skin biopsy culture re-
vealed infection with M. tuberculosis complex. Table 3
shows the incidence rates for TB and the predictive values
for progression to TB according to each diagnostic test.DISCUSSION
This study aimed to determine the ability of the QFT-GT
to predict the development of active TB in patients undergo-
ing LTand HSCT. Our findings reveal a poor positive predic-
tive value of QFT-GT for progression, which is comparable
to that of the TST. Only 1 (4.5%) QFT-GT-positive patientTABLE 2.




TST Positive 18a 4 1
No. Risk F 21,2 21,4 —
Negative 4 22 1
No. Risk F — 22,3 —
Global 22 26 2
a Case 1: a 67-year-old Spanish man developed disseminated TB 387 days after LT (and 532 days after LT
liver transplantation for hepatocellular carcinoma.
b Case 2: a 46-year-old Spanish woman developed disseminated TB 100 days after HSCT (and 116 days aft
The reason for practicing an unrelated allogeneic bone marrow transplant was an acute leukemia.
Indet, indeterminate. No. Risk F: Number of patients with risk factors for TB, as described: being born in a
Copyright © 2015 The Authors. Transplantation Diamong LT recipients, and none of the QFT-GT-positive
HSCTrecipients, developed TBwithin 3.5 years of transplan-
tation. However, the risk of developing active TB among
QFT-GT-negative patients was minimal.
To our knowledge, only 4 studies have reported the inci-
dence of active TB in solid organ transplant recipients
screened with IGRAs.10-13 The incidence of TB in IGRA-
positive patients could only be assessed in 2 that did not offer
preventive therapy.10,11 Kim et al10 reported 4 cases of TB
among 71 T-SPOT.TB-positive patients in a prospective co-
hort of 272kidney transplant recipients,whereas Lange et al11
found no cases of active TB among 25 QFT-GT-positive solid
organ transplant recipients. Furthermore, no cases of TB
occurred among the combined 409 IGRA-negative trans-
plant patients in these retrospective studies. On the con-
trary, in their series of 633 and 87 patients, Jeong et al13
and Theodoropoulos et al12 described 1 (1.1%) and 2
(0.3%) cases of TB in QFT-GT–negative transplant patients,
respectively. Although there is limited data available on
IGRAs in HSCT recipients,11,14 these also report low posi-
tive and very high negative predictive values for progression
to active TB.
A recent study assessed the TST and both IGRAs to iden-
tify patients at risk for TB in different groups of immunocom-
promised patients in Europe.16 Although it included a large
number of solid organ transplant and HSCT recipients, both
LTBI tests were carried out after the transplant procedure.
Their results, including a high unexpected rate of indetermin-
ate results, are therefore not comparable with the present study.
There is no consensus on whether TST or IGRAs should
be used to assess the risk of transplant-associated TB and ulti-
mately prevent it.6 This uncertainty may be linked to the scar-
city of longitudinal data of simultaneous screening with both
tests, together with the inability of either test to predict the
development of active TB.16-18 In our study, incidence of
TB and predictive values for TB progression either in the LT
cohort or the HSCT cohort did not differ significantly with
the 2 tests. Although 2 series of kidney andHSCT patients re-
ported a higher incidence of TB in IGRA-positive than in
TST-positive patients, the differences were not statistically
significant.10,14 These results are consistent with those re-
ported in a previous meta-analysis, in which IGRAs showed
a modest, but higher positive predictive value for TB prog-
ression than the TSTwith and without risk stratification.17actors for Both Cohorts
HSCT Candidates
QFT-GT
Global Pos Neg Indet Global
23 5 3 0 8
12 11 —
27 2 16b 0 18
— 21 —
50 7 19 0 26
BI screening). He had no specific TB risk factors and had tested positive for TST and QFT while awaiting
er LTBI screening). He had tested negative for both TST and QFT. She had no specific risk factors for TB.
high-prevalence TB country1, previous TB close contact2, health worker3, (ex-) intravenous drug user4.
rect. Published by Wolters Kluwer Health, Inc.
TABLE 3.
The Incidence of Active Tuberculosis, and Positive Predictive Value of QFT-GT and TST in Liver and Hematopoietic Stem-Cell
Transplant Recipients
Liver Transplant (n = 50) Hematopoietic Stem Cell Transplant (n = 26)
QFT-GT-positive 22 7
Median follow-up, mo 37.9 (35.8-54.2) 55.9 (33.0-57.1)
Person-years, p-y 81.5 25.9
TB cases 1 0
Incidence rate of TB cases per 100 p-y (95%CI) 1.2 (0.1-6.1) —
PPV (95% CI) 4.5 (0.8-21.8) —
QFT-GT-negative 26 19
Median follow-up, mo 42.0 (30.7-51.2) 47.3 (29.1-55.9)
Person-years, p-y 83.3 65.4
TB cases 0 1
Incidence rate of TB cases per 100 p-y (95%CI) — 1.5 (0.1-7.5)
NPV (95%CI) 100 (87.1-100) 94.7 (75.4-99.1)
TST-positive 23 8
Median follow-up, mo 44.8 (35.4-52.1) 51.6 (24.8-59.1)
Person-years, p-y 75.0 29.3
TB cases 1 0
Incidence rate of TB cases per 100 p-y (95%CI) 1.3 (0.1-6.6) —
PPV (95%CI) 4.4 (0.8-21.0) —
TST-negative 27 18
Median follow-up, mo 50.8 (34.2-56.7) 47.5 (27.0-57.5)
Person-years, p-y 99.6 62.1
TB cases 0 1
Incidence rate of TB cases per 100 p-y (95% CI) — 1.6 (0.1-8)
NPV (95% CI) 100 (87.5-100) 94.4 (74.2-99.0)
PPV indicates positive predictive value; NPV, negative predictive value.
4 Transplantation DIRECT ■ 2015 www.transplantationdirect.comThe major advantage of IGRAs over the TST in healthy
people in low-prevalence settings is that it can reduce the num-
ber of people considered for preventive chemotherapywithout
increasing the risk of subsequent active TB.19 Although this
characteristic cannot be applied to immunocompromised pa-
tients, in whom IGRAsmay not save LTBI diagnostics as com-
pared with TST, the negative predictive value of IGRAs for
progression to active TB is consistently high in this popula-
tion, and probably better than that of the TST.17
Therefore, with the current data available, the choice of
TST or IGRAs for screening transplant candidates should
be based on the expected specificity in each setting, opera-
tional factors, logistics, patients' preferences, and cost; and
always keeping in mind that a negative result does not rule
out the future risk of developing TB.16
The main limitation of our study is the small sample size
and the low progression rate during follow-up, both of which
preclude an accurate estimation of the incidence and predic-
tive values for progression to active TB.
In conclusion, the rate of posttransplant TB among QFT-
GT-positive patients was both low and comparable to that
of the TST in this cohort of LT and HSCT recipients. Our re-
sults add to the evidence that IGRAs are poor at predicting
the development of active TB in transplant recipients.REFERENCES
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